Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis has launched Lercanidipine in five European countries. Lercanidipine is mainly used to treat high blood pressure.
Subscribe to our email newsletter
Actavis has launched the product under its own brand name on day one in the UK and France, where the patents expired on 20 and 21 January, respectively. The product was also launched on day one in France, the UK, the Netherlands, Belgium and Italy by clients of Medis, Actavis’ third-party sales division.
Lercanidipine Actavis will be launched in various other European countries as patents expire in the near future.
Lercanidipine tablets, indicated for hypertension, are the generic equivalent of Zanidip and Lercadip. The tablets are available in 10mg and 20mg dose.
Generic Lercanidipine was developed by Actavis in Iceland and is manufactured by the company in Malta.
Iceland-based Actavis is a global developer, manufacturer and distributor of generic pharmaceuticals.